A Multicenter, Prospective, Randomized, Double-Blind Trial of Basiliximab in Heart Transplantation

Mehra, Mandeep R.; Zucker, Mark; Wagoner, Lynne E.; Michler, Robert E.; Boehmer, John; Kovarik, John M.; Vasquez, Arthur

doi:10.1016/j.healun.2004.09.010

Cited by 96 publications

(81 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Based on their effectiveness in reducing acute rejection in renal [24,25] and cardiac transplant [26,27], and favorable side effect profiles, these agents became the most common form of induction in lung transplant recipients shortly after their introduction in the late 1990s [28,29] (Fig. 1).…”

Section: Ishlt Registrymentioning

confidence: 99%

Induction therapy in lung transplantation

Sweet

2013

Transpl Int

View full text Add to dashboard Cite

Strategies for induction in lung transplant recipients typically mirror those used in other solid organ transplant recipients. Polyclonal (Atgam, RATG) and monoclonal (OKT3) T-cell depleting agents, IL-2 Receptor antagonists (basiliximab and daclizumab) have been used most commonly. In spite of evidence from ISHLT registry reports that induction reduces acute rejection and has a small benefit in freedom from bronchiolitis obliterans and long-term survival, other studies have been less convincing in terms of long-term benefit. Future iterations of induction strategy for lung transplant recipients will hopefully utilize tolerogenic approaches currently being tested in renal transplantation.

show abstract

Section: Ishlt Registrymentioning

confidence: 99%

Induction therapy in lung transplantation

Sweet

2013

Transpl Int

View full text Add to dashboard Cite

show abstract

“…Table 22 summarizes adverse reactions reported with basiliximab. [252][253][254][255][256][257][258][259][260][261][262][263] Table 23 summarizes the use of basiliximab in two studies of lung transplant patients . 265,266 Table 24 summarizes 16 studies in which the drug was administered for nonpulmonary indications.…”

Section: Il-2 Receptor Antagonistsmentioning

confidence: 99%

“…265,266 Table 24 summarizes 16 studies in which the drug was administered for nonpulmonary indications. [252][253][254][255][256][257][258][259][260][261][262][263][267][268][269][270] These studies were included in the table because they provided signifi cant information regarding toxicity.…”

Section: Il-2 Receptor Antagonistsmentioning

confidence: 99%

Monitoring of Nonsteroidal Immunosuppressive Drugs in Patients With Lung Disease and Lung Transplant Recipients

Baughman

Meyer

Nathanson

et al. 2012

Chest

View full text Add to dashboard Cite

Objectives: Immunosuppressive pharmacologic agents prescribed to patients with diffuse interstitial and infl ammatory lung disease and lung transplant recipients are associated with potential risks for adverse reactions. Strategies for minimizing such risks include administering these drugs according to established, safe protocols; monitoring to detect manifestations of toxicity; and patient education. Hence, an evidence-based guideline for physicians can improve safety and optimize the likelihood of a successful outcome. To maximize the likelihood that these agents will be used safely, the American College of Chest Physicians established a committee to examine the clinical evidence for the administration and monitoring of immunosuppressive drugs (with the exception of corticosteroids) to identify associated toxicities associated with each drug and appropriate protocols for monitoring these agents. Methods: Committee members developed and refi ned a series of questions about toxicities of immunosuppressives and current approaches to administration and monitoring. A systematic review was carried out by the American College of Chest Physicians. Committee members were supplied with this information and created this evidence-based guideline. Conclusions: It is hoped that these guidelines will improve patient safety when immunosuppressive drugs are given to lung transplant recipients and to patients with diffuse interstitial lung disease. CHEST 2012; 142(5):e1S-e111SAbbreviations: ACCP 5 American College of Chest Physicians; ALT 5 alanine aminotransferase; ATG 5 antithymocyte globulin; CHF 5 congestive heart failure; CMV 5 cytomegalovirus; CNI 5 calcineurin inhibitor; COI 5 confl ict of interest; CsA 5 cyclosporin A; FDA 5 US Food and Drug Administration; HBV 5 hepatitis B virus; HMG-CoA 5 b -hydroxy-bmethylglutaryl-coenzyme A; HSP 5 Health and Science Policy Committee; IL2RA 5 IL-2 receptor a ; ILD 5 interstitial lung disease; IPF 5 idiopathic pulmonary fi brosis; ITP 5 idiopathic thrombocytopenia purpura; LAM 5 lymphangioleiomyomatosis; MESNA 5 sodium 2-sulfonylethanesufonate; MPA 5 mycophenolic acid; mTOR 5 mammalian target of rapamycin; PTLD 5 posttransplant lymphoproliferative disease; RCT 5 randomized controlled trial; SIRS 5 systemic infl ammatory response syndrome; TNF 5 tumor necrosis factor; TPMT 5 thiopurine methyltransferase

show abstract

“…9 Although induction agents such as monoclonal antibodies supplanted the older polyclonal induction agent Muromonab-CD3 (Orthoclone OKT3), evidence for a benefit was less forthcoming. 10,11 Another important shift in the recipient characteristic was the slow but definite growth of mechanical circulatory support as a bridge to transplantation and recognition that the presence of this durable device resulted in distinct immunologic perturbations in the host. Indeed, by 2009, a third of all recipients undergoing transplantation were so bridged under support with a durable mechanical device.…”

Section: Era Effects In Transplant Recipient Managementmentioning

confidence: 99%